Sanofi shelves four assets, including mid-stage dwarfism candidate
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies.
The French pharma deprioritized a Phase 2 drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
